The obesity duopoly has been pierced as Amgen positions itself to have a drug on the market in a few years. While this adds ...

Welcome to the Third Quarter 2024 Novo Nordisk A/S Earnings Conference Call. At this time, all participants are in a listen-only mode. After the speakers' presentation, there will be a question ...

Novo Nordisk is encouraged by White House proposals that could support patients using weight-loss drugs, but cautioned that ...

Novo Nordisk and Ypsomed’s 2023 deal is rumoured to include an autoinjector supply for potential Wegovy successor CagriSema.

The world’s largest philanthropic fund that ultimately controls Novo Nordisk A/S will ramp up its investments outside of ...

“Novo Nordisk expects to file for regulatory approvals in the U.S. and EU in the first half of 2025. The detailed results from ESSENCE will be presented at a scientific conference in 202 ...

Novo Nordisk expects to file for regulatory approvals in the US and EU in the first half of 2025. The detailed results from ESSENCE will be presented at a scientific conference in 2024.

While Novo Nordisk and Lilly are the undisputed leaders in weight management right now, a number of pharmaceutical companies ...

Good day, and thank you for standing by. Welcome to the third-quarter 2024 Novo Nordisk A/S earnings conference call. [Operator instructions] Please be advised that today's conference is being ...

Welcome to the Third Quarter 2024 Novo Nordisk A/S Earnings Conference Call. At this time, all participants are in a listen-only mode. After the speakers' presentation, there will be a question ...